This is a preview of subscription content, log in via an institution to check access.
Notes
2015 US dollars
Reference
Miller JD, et al. Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US. ClinicoEconomics and Outcomes Research 2016: 215-226, No. 8, 20 May 2016. Available from: URL: http://dx.doi.org/10.2147/CEOR.S98888
Rights and permissions
About this article
Cite this article
Edoxaban dominates rivaroxaban for stroke prevention in NVAF. PharmacoEcon Outcomes News 754, 13 (2016). https://doi.org/10.1007/s40274-016-3083-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-3083-4